July 16-18 | Boston, MA
www.tumor-models.com

BOOK BEFORE JUNE 7 TO SAVE UP TO $400!

7th Annual
PREDiCT: TUMOR MODELS BOSTON

Arming Preclinical Cancer Research Through Enhanced Model Confidence

38 Preclinical Oncology Leaders Including:

Corinne Reimer
Associate Director - In Vivo Pharmacology
AstraZeneca

Davy Ouyang
Executive Director
Crown Bioscience

Sarah Knutsen
Director, Preclinical Biology
Twentyeight-Seven Therapeutics

Rhys Jones
Senior Director, DMPK
Pfizer

Kerry Whalen
Director - Discovery & Translational Biology
Tarveda Therapeutics

Enrique Alvarez
Director - Preclinical Development
Kleo Pharmaceuticals Inc.

Expertise Partners:
The Jackson Laboratory — Leading the search for tomorrow's cures
MITRA BIOTECH

Lead Partner:
CrownBio — CONNECTING SCIENCE TO PATIENTS

Spotlight Partners:
hera BioLabs
BIOVOLUME FUEL 3D — SHAPING FUTURES
Bioresearch — Advancing Your Preclinical Oncology
pharmatest
FUJIFILM — Value from Innovation
VISUALSONICS

Tel: +1 617 455 4188 **Mail:** info@hansonwade.com Tumor Models

hansonwade

WHAT TO EXPECT

120 Attendees

30+ Case Studies

10 Q&A Sessions

10 Hours of Discussion

Navigate the Maze of Cancer Models & Drive Translational Decision Making

The evolution in the treatment paradigm has stimulated rapid developments in the design and application of more predictive preclinical cancer models.

New treatment classes such as multimeric antibodies and cell/gene therapies, alongside advances in targeted therapeutics have demanded a greater emphasis on the selection, characterization and effective use of tumor models.

The **7th Annual PREDiCT: Tumor Models Boston** summit will explore robust preclinical strategies utilizing current and emerging model systems to overcome core challenges across the early stages of cancer drug development. Presentations will span preclinical strategies validating new anticancer drugs, assessing therapeutic index and identifying surrogate markers of tumor progression.

Plug into a network of preclinical and translational scientists seeking to share methods for the rational design of combinations, patient stratification and identify new strategies to model metastasis, resistance and sensitivity.

Hear what previous attendees have to say

"Thank you for putting on an excellent and thought provoking conference I found this an extremely enjoyable meeting and appreciated the diversity of approaches used by the different speakers to address their specific needs."

Principal Scientist, COI Pharmaceuticals

"It's not just about CRO marketing seminars. This is a really nice small boutique conference focused on the most recent breakthroughs on the mechanistics of tumor models and ex vivo models. Positively surprised of the quality of conference."

PI, Angarus Therapeutics

Your Unmissable Keynotes in 2019:

Rationally Designing Combination Therapies to Enhance Immunotherapeutic Response

Explore non-clinical approaches to overcome development challenges with presentations from **Dicerna & Takeda**

Identifying Which Model, Why and When

Hear presentations from **Tesaro** and **Kleo Pharmaceuticals** on how they've been selecting and characterizing available models to support translation towards the clinic

Modeling the Tumor Microenvironment to Enhance Clinical Effectiveness

Understand the biological crosstalk within the TME between immunosuppressive factors and immune cells with insights from **Novartis** & **Pharmatest**

Identifying Strategies to Mitigate Therapeutic Resistance

Leave with actionable take-aways on models supporting **AstraZeneca's** therapeutic efforts

Additive Tools Enhancing the Predictive Power of Models

Hear how CRISPR, imaging and high content approaches are providing new depths of insights for researchers at **MD Andserson, NIH** and **GSK**

YOUR EXPERT SPEAKERS

Alejandro Amador
Head, Scientific Leader Discovery Biology Automation
GSK

Andrew Rhim
Associate Director - Translational Research & Assistant Professor – Gastroenterology
MD Anderson Cancer Center

Anna Bunin
Associate Director - Immunology
Kleo Pharmaceuticals Inc.

Chen Zhao
Clinical Fellow
National Institutes of Health

Daniel Gioeli
Associate Professor
University of Virginia

Corinne Reimer
Associate Director - In Vivo Pharmacology
AstraZeneca

Dan Powell
Director - Clinical Tumor Tissue Facility & Associate Professor
University of Pennsylvania

Davy Ouyang
Executive Director
Crown Bioscience

Enrique Alvarez
Director - Preclinical Development
Kleo Pharmaceuticals Inc.

Esmaiel Jabbari
Professor
University of South Carolina

Stephane Gesta
VP, R&D and Science Strategy
Berg Pharma

Fangxian Sun
Lead Investigator - Research Pharmacology
Sanofi

Fred Roberts
Sales Manager
Fujifilm Visual Sonics

Geeta Sharma
Scientific Fellow, Translational Research
Tesaro

Haluk Yuzugullu
Associate Principal Scientist, PDX Model Team Lead, Oncology Bioscience
AstraZeneca

Hongmin Chen
Principal Scientist
Merck

Jenni Bernoulli
COO
Pharmatest Services

Juan Delgado
Lead Data Scientist
Fuel3D

Keiji Furuuchi
Associate Director & Head of Immunotherapy & Preclinical Development
Eisai

Kerry Whalen
Director - Discovery & Translational Biology
Tarveda Therapeutics

Lindsey Crowley
Scientist
EMD Serono

Maryland Franklin
Vice President – Scientific Development
MI Bioresearch

Mike Brehm
Professor
University of Massachusetts

Mithun Khattar
Scientist & Immuno-Oncology Lead
Takeda

Natalia Malkova
Lab Head/ Principal Research Investigator
Sanofi

Neil Michaud
Director, Translational Medicine
EpiZyme

Omid Ghasemi
Scientist I, Imaging
Takeda

Rhys Jones
Senior Director, DMPK
Pfizer

Rick Huntress
Director of Commercial Business Development
The Jackson Laboratory

Sarah Knutsen
Director, Preclinical Biology
Twentyeight-Seven Therapeutics

Shanthi Ganesh
Associate Director
Dicerna Pharmaceuticals Corp.

Shiva Kazerounian
Principal Scientist, In Vivo Pharmacology Lead
Berg Pharma

Shuxi Qiao
Senior Scientist Internal Medicine Research Unit
Pfizer Inc.

Silvia Goldoni
Investigator & Head of Oncology Lab
Novartis

Stefan Jellbauer
Technical Liaison for Translational Applications
Mitra Biotech

Joshua Breunig
Associate Professor & Board of Governors, Regenerative Medicine
Cedars-Sinai Medical Centre

Tseten Jamling
VP of Research and Development
Hera Biolabs

Yvonne Evrard
Operations Manager
National Institute of Health Sciences

WORKSHOP DAY JULY 16 2019

Workshop A

Challenges, Insights & Future Directions for Experimental Models in Cancer Immunotherapy

8.00am - 11.00am

Understanding tumor placement, immune composition, response to treatment and molecular characterization for the model of interest can be invaluable when designing the most appropriate study for your research goals. However, major issues remain, not only in selecting and optimizing models and tools for cancer immunotherapy research, but in selecting who to work with and when.

Discussions in this session will center on:

- The range of current IO models available amongst their strengths and weaknesses
- Mouse syngeneic models, their genetic backgrounds and use in IO for mono or combination therapy
- How to identify, select and work with model developers and CRO's available

Workshop Leader
Shiva Kazerounian
Principal Scientist, In Vivo Pharmacology Lead
Berg Pharma

Workshop B

Introduction & Overview to 3D High Content Screening Approaches

11.30am - 2.30pm

3D high content approaches offer significant opportunity for improving cancer drug discovery. However, there exists formidable technical hurdles for HCS methods and analytical approaches. The session will look to explore the current start-of the art alongside the emergence of new technologies and techniques enabling 3D HCS applications. Discussions will center on the marriage of 3D and high-content screening (HCS) to discover targeted cancer drug therapies.

Leave having explored:

- The value, impact and approaches for use of 3D-HCS within cancer discovery
- 3D High-content analysis algorithm approaches for HCS
- How multiparametric analyses can be incorporated to evaluate phenotypic compound effects

Workshop Leader
Alejandro Amador
Head, Scientific Leader Discovery Biology Automation
GSK

WORKSHOP DAY JULY 16

Workshop C

Considerations in Modeling the Microenvironment

3.00pm - 6.00pm

In the last few decades, cancer stem cells (CSC) have proven to play a key role in tumor initiation resistance and recurrence. Recent advances have also begun to elucidate the complex cross talk at different stages of tumor progression between the TME and CSC's. This session aims to provide an insight into the role and importance of CSC's in the context of the ME as well as examine the clinical implications of targeting these interactions.

Topics to be covered include:

- Current state of the art for modeling the TME interactions in the context of the CSC niche
- The importance of CSC TME interactions alongside potential therapeutic targets for the development of more effective treatments against cancer
- The significance of stromal cells, immune cells, extracellular matrix, tumor stiffness, and hypoxia in regulation of CSC plasticity and therapeutic resistance

Workshop Leader
Esmaiel Jabbar
Professor
University of South Carolina



"The conference was very informative. I especially enjoyed the pre-conference workshops. I learned a great deal about the pros and cons of the models used for immunotherapy."

Senior Director, Immunology, Calvert Laboratories Inc.

"The meeting was a great mix of new technologies and scientific insight into solving some of the major problems in this area."

Senior Director, Celgene

CONFERENCE DAY ONE
JULY 17 2019

7.30 **Registration, Coffee & Networking**

8.20 **Chair's Opening Remarks**

The Changing Expectations of Model Requirements

Natalia Malkova
Lab Head/ Principal Research Investigator
Sanofi

8.30 **Experiment with Immune Targeting Therapeutics Agents & Synthetic Mouse Model**

- Defining your strategy and identifying your parameters in the micro-environment
- Progressing into clinics – validation requirements

Davy Ouyang
Executive Director
Crown Bioscience

8.55 **Developing Human Target Knock-In Mouse Models for Immuno-Oncology Drug Discovery**

- Lack of animal models for preclinical efficacy evaluation of human therapeutic antibodies for cancer immunotherapies
- HuGEMM mouse models, created by knocking in chimeric checkpoint targets with human extracellular domains; together with HuCELL syngeneic tumor lines, expressing human TAAs, offer a robust platform for efficacy and safety assessment, as well as MOA of specific human biological therapeutics in vivo

Mike Brehm
Professor
University of Massachusetts

9.20 **Opportunities & Challenges in Utilizing Humanized Mice to Model Human T Cell Responses**

- Exploring recent advances in humanized models with a natural and translationally relevant tumor microenvironments in enabling the effective preclinical characterization and pharmacodynamic evaluation of IO therapeutics
- Discussing the remaining challenges and potential for these mice in rational combination design to antitumor responses and minimize tumor escape

Rick Huntress
Director of Commercial Business Development
The Jackson Laboratory

9.45 **Addressing the Demand for Clinically Relevant Models in IO Research**

- Understand how animal models can provide accurate in vivo conditions to mimic the natural tumour environment
- Presenting data on how these humanized models in combination with patient-derived xenografts can be used to study immune checkpoint blockade
- Providing valuable insights in predicting both combinatorial therapy efficacy, identifying unmet clinical needs, improving the value of preclinical modeling and ultimately impacting patient outcomes in the clinic

10.10 **Panel Discussion - The Changing Expectations of Model Requirements**

Davy Ouyang
Executive Director
Crown Bioscience

Mike Brehm
Professor
University of Massachusettes

Natalia Malkova
Lab Head/
Principal Research Investigator
Sanofi

Rick Huntress
Director of Commercial Business Development
The Jackson Laboratory

10.30 **Speed Networking**

11.00 Morning Refreshments

Advances in Preclinical and Translational Imaging

11.30 Ultrasound Imaging of Patient-Derived Xenograft to Investigate Intratumoral Heterogeneous Response

- Demonstrating chicken embryo as a receptive and highly efficient host for patient-derived xenograft modeling, allowing for multiregional "tumor avatar" studies
- Showcasing how ultrasound imaging can provide rapid, reproducible, and high-resolution quantification of tumor volume, blood flow, and perfusion
- Functional tumor heterogeneity, in the context of systemic and immune-therapies, exists at the time of nephrectomy and is a phenotype-based readout of genetic tumor heterogeneity

Fred Roberts, Sales Manager, **Fujifilm Visual Sonics**

11.45 Characterization of Mouse Syngeneic Tumor Models Using Multiplex T Cell Panel

- Discussing the workflow for establishment of multiplex T cell panel assay validation and image analysis
- Exploring the spatial infiltration of T cells in tumor microenvironment and its implications on tumor behaviour in syngeneic mouse tumor models
- Discussing the translational importance of multiplex T cell panel quantitative analysis in decision making for drug candidate selection and patient selection in clinic: a pharmacodynamic case study

Omid Ghasemi, Scientist I, Imaging, **Takeda**

12.10 Using 3D Imaging & AI to Advance Preclinical Cancer Research

- The benefits of digitising subcutaneous tumour measurement – greater accuracy, reproducibility and traceability
- How Fuel3D's BioVolume solution can power better science and improve the early discovery of biomarkers

Juan Delgado, Lead Data Scientist, **Fuel3D**

12.25 Using Clearing-Enhanced 3D (Ce3D) to Dissect Tumor Immune Microenvironment in Genetically Egineered Mouse Models

- Investigating immune cell populations in 3D
- Combining transcriptomic analysis and Ce3D to study the functions of immune cells in tumor microenvironment
- Visualizing lung microbiota in lung adenocarcinoma

Chen Zhao, Clinical Fellow, **National Institutes of Health**

12.50 Q&A Panel - Advances in Preclinical & Translational Imaging

Omid Ghasemi, Scientist I, Imaging, **Takeda**

Chen Zhao, Clinical Fellow, **National Institutes of Health**

Advancing Biologic Therapeutics

11.30 Beyond just Xenografts: Preclinical Models Combinations to Reveal True Capabilities in ADC Development

- HALAVEN as payload conjugated ADCs showed superior anti tumor effect in various tumor models
- HALAVEN exhibit unique effects in tumor microenvironment in various xenografts model
- Importance of payload selection of ADC for clinical development is to be discussed

Keiji Furuuchi, Associate Director & Head of Immunotherapy & Preclinical Development, **Eisai**

11.55 Potent & Target Selective Miniaturized Drug Conjugates for the Treatment of Cancer

- Revealing insights into the Pentarin platform
- Exploring the utility of in vitro and in vivo models in understanding efficacy, sustained accumulation, balancing pharmacokinetics and pentration of mini-drug conjugates
- Discussing the preclinical validation of Tarveda's emerging preclinical pipeline

Kerry Whalen, Director - Discovery & Translational Biology, **Tarveda Therapeutics**

12.20 How to Build a Translational Platform to Develop Effector Cell Centered Immuno-Oncology Agents

- Presenting on the KLEO toolbox
- Highlighting the design and optimisation of novel models engrafted with NK cells to explore NK depletion
- Sharing model validation strategies against recognized targets with agents that activate cellular effector functions

Enrique Alvarez, Director - Preclinical Development, **Kleo Pharmaceuticals Inc**

Anna Bunin, Associate Director - Immunology, **Kleo Pharmaceuticals Inc.**

12.45 Q&A Panel - Advancing Biologic Therapeutics

Keiji Furuuchi, Associate Director & Head of Immunotherapy & Preclinical Development, **Eisai**

Kerry Whalen, Director - Discovery & Translational Biology, **Tarveda Therapeutics**

Enrique Alvarez, Director - Preclinical Development, **Kleo Pharmaceuticals Inc**

Anna Bunin, Associate Director - Immunology, **Kleo Pharmaceuticals Inc.**

1.10 Lunch

Engineering & Targeting the Microenvironment

2.10 Applications of An In-Vitro Multi-Cell Model of the Tumor Microenvironment

- Describing the development and validation of a novel multi-cellular 3D in vitro system for pancreatic cancer and non-small cell lung carcinoma
- Recreating multiple aspects of cancer biology through the combination of microvascular endothelial cells exposed to tumor hemodynamics, stromal cells and tumor
- Highlighting its applications for the development of effective anticancer agents and implications for patient avatars

Daniel Gioeli, Associate Professor, **University of Virginia**

2.35 Attention to Metastasis: Understanding Importance of Tumor Microenvironment In Immunotherapy Development

- Significance of preclinical metastasis models
- Triple-negative breast cancer primary tumor and bone metastasis models in humanized mice and effects of immunotherapy
- Estrogen receptor positive breast cancer models: importance to follow adverse reactions of estrogen and immunotherapies

Jenni Bernoulli, COO, **Pharmatest Services**

2.50 Modeling Tumour Immunity *In Vitro* for Target Identification and Validation

- Performing compound profiling of targeted IO combination therapies in 3D models to aid in vitro in vivo translation
- Analyzing immune suppressive features of co-culture
- Highlighting the applications of co-culture to profiling targeted therapies using multiple readouts

Silvia Goldoni, Investigator & Head of Oncology Lab, **Novartis**

3.15 Q&A Panel – Engineering & Targeting The Microenvironment

Silvia Goldoni, Investigator & Head of Oncology Lab, **Novartis**

Daniel Gioeli, Associate Professor, **University of Virginia**

Novel Models for Novel Targets

2.10 OncoRat® Enables Faster Establishment of PDX Models in Fewer Passages

- Model engraftment rates are increased 67% in comparison to mouse for nonsmall cell lung cancer (NSCLC) patient samples
- OncoRat delivers tumor masses 10x that of mouse models in half the time – making PDX studies possible after a single passage, decreasing the risk of genetic drift and host-specific tumor evolution from multiple passages as observed in mice

Tseten Jamling, VP of Research and Development, **Hera Biolabs**

2.25 Defining & Exploiting Metabolic Vulnerabilities of Cancer

- Exploring novel metabolic vulnerabilities of subtype of Ras-mutant tumors
- Exploiting the identified vulnerabilities by pharmacological intervention

Shuxi Qiao, Senior Scientist Internal Medicine Research Unit, **Pfizer Inc.**

2.50 Engineering the Immune System: GEMM Models as Preclinical Bridge for Translational Cancer Research

- Demonstrating the impact of GEM induced lymphoma models in translating tazemetostat from clinical proof of concept
- Highlighting in vivo antitumor activity of tazemetostat against DLBCL models with mutant EZH2 translates to objective responses in NHL patients

Neil Michaud, Director, Translational Medicine, **EpiZyme**

3.15 Q&A Panel - Novel Models For Novel Targets

Shuxi Qiao, Senior Scientist Internal Medicine Research Unit, **Pfizer Inc.**

Neil Michaud, Director, Translational Medicine, **EpiZyme**

3.35 Afternoon Refreshments

Modeling Cancer Drug Resistance

Maryland Franklin
Vice President – Scientific Development
MI Bioresearch

4.05 Syngeneic Models of Breast and Ovarian Cancers: Effects of Immune Modulatory Agents in Classically "Cold" Tumors

- Utilization of murine breast cancer models in preclinical immuno-oncology pharmacology
- Pros and cons of the 4t1 mammary cancer model
- Characteristics of alternative syngeneic breast models
- Responses of a new model to checkpoint inhibition and T cell costimulation

Corinne Reimer
Associate Director - In Vivo Pharmacology
AstraZeneca

4.30 Translational Strategies to Overcome Primary, Acquired & Adaptive Resistance

- Understanding the potential of humanized and syngeneic models in recapitulating the tumor microenvironment
- Showcasing the generation humanized systems to validate targets in the myeloid compartment to overcome resistance
- Exploring approaches to analyze MDSCs in humanized PDx models

Stefan Jellbauer
Technical Liaison for Translational Applications
Mitra Biotech

4.55 Capturing Drug-Induced Modulation of the Tumor Microenvironment Using A Personalized Ex Vivo Histoculture Approach

- Mitra Biotech has developed and clinically validated our fully human ex vivo platform technology (CANscript™)
- CANscript ™ uses fresh patient material (tumor, autologous ligands and PBMCs) to explore the mechanism of action by employing customizable endpoint assays
- This talk will focus on how we use CANscript to explore the effect of checkpoint inhibitors alone and in combination with SOC as well as oncolytic virus to answer development-critical questions

5.20 Q&A - Modeling Cancer Drug Resistance

Corinne Reimer
Associate Director - In Vivo Pharmacology
AstraZeneca

Stefan Jellbauer
Technical Liaison for Translational Applications
Mitra Biotech

5.50 Close of Conference Day One

CrownBio
CONNECTING SCIENCE TO PATIENTS

6.00 Evening Drinks Reception & Poster Session Hosted by Crown Bioscience

"Great group of researchers, great talks and an excellent focus on model generation an rationale. I learned an amazing amount about setting up in vivo models for IO studies to enable development of next generation oncology treatments."

Scientist II, Verseon Corporation

CONFERENCE DAY TWO
JULY 18 2019

8.00 Coffee & Networking

Strategy – Selection – Characterization

Geeta Sharma
Scientific Fellow, Translational Research
Tesaro

9.00 Providing Translational Support for TSR Programs
- Presentation details to be confirmed

Dan Powell
Director - Clinical Tumor Tissue Facility & Associate Professor
University of Pennsylvania

9.25 Models to Understand the Mechanisms of Action of Cancer Biologic Therapies
- Showcasing the testing of new antibody combinations that activate tumor-reactive T cells and simultaneously blocking checkpoint molecules that dampen host antitumor immunity
- Revealing the development of new model systems to screen immunomodulatory agents in vitro and in vivo

9.50 Q&A Panel - Strategy – Selection – Characterization

Geeta Sharma
Scientific Fellow, Translational Research
Tesaro

Dan Powell
Director - Clinical Tumor Tissue Facility & Associate Professor
University of Pennsylvania

10.20 Morning Refreshments

Precision Gene Editing for Disease Modeling and Target Validation

11.05 Applications of Next Generation Genetic Engineering Approaches
- Overview of GEM models and progress towards further humanizing and recapitulating the immune response at earlier immune privileged states
- Moving towards organoids, The advantages of developing CRISPR-edited tumoroids in vitro to study specific tumor-driven pathways
- Exploring how to develop flexible strategies with iPSC derived organoids cultures to maximize predictability and translatability of early discoveries

Andrew Rhim, Associate Director - Translational Research & Assistant Professor – Gastroenterology, **MD Anderson Cancer Center**

Models and Strategies to Bridge the Combination Gap

11.05 Designing RNAi Combination Regimes Targeting Immunotherapy Resistant Patient Populations in Cancer
- Highlighting the opportunity and preclinical models supporting RNAi therapeutics targeting the 'undruggable' in IO
- Exploring translational strategies for overcoming resistance in patient populations by synergistically targeting oncogenic pathways and other suppressive pathways using RNAi drugs and small molecule inhibitors
- Discussing the biomarker strategy to support the rational design of RNAi-containing drug combinations

Shanthi Ganesh, Associate Director, **Dicerna Pharmaceuticals**

11.30 Transgenic Manipulation of Tumor Organoids for "Personalized" Modeling of Diverse Tumor Subtypes

- Strategies for combining single-copy somatic transgenesis with CRISPR genome editing to generate patient-derived mutation signatures in in vivo mouse and 3D human organoid models to accurately model clinical tumor subtypes in a "personalized" manner
- Methodologies for interrogating human tumor heterogeneity over space and time as well as for credentialing of models with single-cell RNA sequencing
- Examples of preclinical studies investigating strategies to impede tumor growth and development by immunotherapy, metabolic targeting, and therapeutic mimicry

Joshua Breunig, Assistant Professor, **Cedars-Sinai Medical Center**

11.30 Preclinical Development & Translational Challenges in Predicting the Value of Emerging Cancer Immunotherapies

- Exploring preclinical development challenges in modeling checkpoint modulators and IO combinations
- Highlighting the translatability of pre-clinical murine models for investigating combination therapies

Mithun Khattar, Scientist & Immuno- Oncology Lead, **Takeda**

11.55 Using 3D Tumor Models to Investigate the Role of Immune Cells on the CSC Niche

- Discussing the role of Cancer Stem Cell and Immune cell interactions in drug response and resistance
- Highlighting novel preclinical models in the development of therapies targeting cancer stem cells
- Exploring the contribution of the CSC niche to tumor initiation and progression and examine the prospects of targeting the niche for cancer therapy

Esmaiel Jabbari, Professor, **University of South Carolina**

11.55 Hematologic Tumor Modeling to Identify Active Combinations in Resistant Settings

- Presentation details to be announced shortly

Haluk Yuzugullu, Associate Principal Scientist, PDX Model Team Lead, Oncology Bioscience, **AstraZeneca**

12.20 Q&A Panel - Precision Gene Editing For Disease Modeling & Target Validation

Andrew Rhim, Associate Director - Translational Research & Assistant Professor – Gastroenterology, **MD Anderson Cancer Center**

Joshua Breunig, Assistant Professor, **Cedars-Sinai Medical Center**

Esmaiel Jabbari, Professor, **University of South Carolina**

12.20 Q&A Panel - Models & Strategies to Bridge the Combination Gap

Shanthi Ganesh, Associate Director, **Dicerna Pharmaceuticals**

Mithun Khattar, Scientist & Immuno- Oncology Lead, **Takeda**

Haluk Yuzugullu, Associate Principal Scientist, PDX Model Team Lead, Oncology Bioscience, **AstraZeneca**

12.40 Lunch

1.40 Round Table Discussions

Picking up on the day's presentations, this session provides you with the opportunity to drive your own learning, crowdsource ideas and discover multiple perspectives for selecting, characterising and building the confidence in tumor model application areas. Over the hour, each breakout will discuss the below questions. Feedback from each group will be collated and presented as part of the moderator panel.

1. Advancing Cancer-Intrinsic Target Research

- Methods for modulating targets and measuring target engagement in vivo
- Considering the effects of intrinsic cancer cell targeting on the tumor microenvironment
- Non-kinase proteins as small molecule drug targets

Sarah Knutsen
Director, Preclinical Biology
Twentyeight-Seven Therapeutics

2. Methods for Modeling & Overcoming Resistant Tumors

- Discussing biological factors associated with response and resistance to in human solid tumours
- Current role and limitations of clinical biomarkers for prediction of response to immunotherapy combos
- Pre-clinical models for predicting drug resistance

Fangxian Sun
Lead Investigator - Research Pharmacology
Sanofi

3. Understanding the Limits of 3D Models as Predictors of Human Disease

- Discussing the value, impact and approaches for use of 3D within cancer research
- Exploring the translatability of 3D Models towards the in vivo setting

Hongmin Chen
Principal Scientist
Merck

4. Evaluating PDX Models as a Tool to Match Biomarkers with Drugs & Drugs With Patients

- Discussing different methods to define response; intermediate response, no response
- Putting a focus of study design and biomarker signature analyses for enhancing model predictivity
- Exploring PDX clinical trial as a tool for Predicting Efficacy for targeted therapies in combination with biomarker identification

Lindsey Crowley
Scientist
EMD Serono

2.30 Moderator Feedback Panel

Sarah Knutsen
Director, Preclinical Biology
Twentyeight-Seven Therapeutics

Fangxian Sun
Lead Investigator - Research Pharmacology
Sanofi

Hongmin Chen
Principal Scientist
Merck

Lindsey Crowley
Scientist
EMD Serono

2.40 Afternoon Refreshments

Models Aiding Dose Translation and Understanding Drug Response

Rhys Jones
Senior Director, DMPK
Pfizer

3.10 Challenges & Opportunities in Understanding Drug Exposure at The Site Of Action Within Pre-Clinical Tumor Models And The Potential Implications of Transporter Mediated Efflux

- Exploring the challenges in evaluating free drug exposure in the tumor models, the methods used to measure and make an estimate relative concentrations observed in plasma
- Examples of differences in exposure in tumors between compounds will be highlighted along with the potential implications when interpreting efficacy data

Yvonne Evrard
Operations Manager
National Institute of Health Sciences

3.35 NCI's Patient Derived Models Repository Quality Control and Preclinical Efforts

- Highlighting the progress towards development of >1000 PDX models along with matched in vitro and organoid models wherever possible
- Showcasing the comprehensive characterization of early-passage models: RNAseq, histology, growth curves, and preclinical drug responses
- Exploring the assessment of tumor heterogeneity on target qualification or clinical response, whether PDXs more faithfully represent the human tumor for pharmacodynamic assay and predictive marker development and if adequately powered preclinical PDX-trials lead to better evaluation of therapies for future clinical use

4.00 Q&A Panel – Models Aiding Dose Translation and Understanding Drug Response

Rhys Jones
Senior Director, DMPK
Pfizer

Yvonne Evrard
Operations Manager
National Institute of Health Sciences

4.20 Close of Conference

2019 PARTNERS

CrownBio
CONNECTING SCIENCE TO PATIENTS

Lead Partner

Our mission is to provide the "gold-standard" collection of well characterized models and services for drug discovery to help our clients reduce the attrition rate of candidate compounds in the clinic, before they enter the clinic. Crown Bioscience, Inc. is a Preclinical CRO with expertise in the disease areas of Oncology and Metabolic Disease. We are known for the breadth and quality of our in vitro and in vivo models, as well as our ability to help clients quantify the real efficacy and pharmacological profile of their candidate before they move into the clinic.

www.crownbio.com

The Jackson Laboratory
Leading the search for tomorrow's cures

Expertise partner

The Jackson Laboratory is a leading provider of cancer mouse models and in vivo oncology services and a National Cancer Institute designated Cancer Center. Drawing on decades of research experience we provide capabilities around model selection, husbandry and customizable oncology studies to help clients and researchers evaluate novel anti-cancer therapies. Our diverse oncology study protocols range from traditional xenograft services to PDX cancer models and advanced humanized mouse models for immuno-oncology drug development.

www.jax.org

MITRA BIOTECH™

Expertise Partner

Mitra Biotech is a global leader in advancing personalized cancer treatment and empowering drug development & discovery. Our unique CANscript™ platform delivers powerful, individualized treatment response predictions — with exceptionally high correlation to clinical outcomes — to inform patient-specific cancer treatment selection and enhance drug discovery.

www.mitrabiotech.com

MI Bioresearch
Advancing Your Preclinical Oncology

Spotlight Partner

MI Bioresearch, a preclinical oncology service provider, offers in vitro services, oncology pharmacology, in vivo imaging, and focal radiation to support research programs. Our team explores the effects of your drugs and biologics using both human and syngeneic models and multi-modality imaging systems. MI provides you with decision-driving data to help advance your drug candidate toward the next cancer research breakthrough. One Focus. One Purpose. Oncology Research.

www.mibioresearch.com

pharmatest

Spotlight Partner

Pharmatest Services Ltd is a CRO offering preclinical efficacy services for the pharmaceutical industry. We offer both in vitro and in vivo models in the fields of oncology and skeletal diseases. In oncology we have special expertise in clinically predictive orthotopic and metastasis models, and especially models of bone metastasis.

www.pharmatest.com

hera BioLabs

Spotlight Partner

Hera Biolabs, Inc., is an innovative pre-clinical CRO utilizing cutting-edge gene-editing technologies to create novel in vivo models for oncology. Given our mission to accelerate cancer research and rug development, we focus upon rat models to deliver translationally-relevant, high-quality results. Using proprietary technologies. Our first SRG model is the OncoRat®, uniquely suited for xenograft studies given its excellent tumor take-rates and ability to deliver masses 10x that of mouse models in half the time – all without the increased risk of genetic drift from multiple passages as observed in mice. Find out more at:

www.herabiolabs.com

2019 PARTNERS

FUJIFILM Value from Innovation | VISUALSONICS

Spotlight Partner

VisualSonics is the world's leading developer of high-resolution, ultrasound-based, in vivo micro-imaging systems designed specifically for non-invasive preclinical research. The company's enabling technology allows researchers at the world's most prestigious pharmaceutical and biotechnology companies, hospitals and universities to conduct research in cardiovascular, cancer, and developmental biology areas. The technology supports applications that include genetic research, phenotypic studies and drug development.

www.visualsonics.com

BIOVOLUME FUEL3D SHAPING FUTURES

Spotlight Partner

Fuel3D are developers of BioVolume™, a subcutaneous tumor scanning and measurement system. Co-developed and deployed in oncology research by leading pharmaceutical company AstraZeneca to replace caliper measurement for analysis of subcutaneous tumors in xenograft models. BioVolume supports Animal Welfare and benefits 3R's across Oncology In vivo Research.

www.fuel3d.com

Stop by the stand for a demonstration of the technology.

studylog®
Animal Study Workflow Software

Exhibition Partner

Studylog's Animal Study Workflow Software® is designed for biomedical animal research and provides features for the design, planning, execution, analysis, and reporting of animal studies in a standardized, highly efficient manner, while protecting data integrity. Reducing many labs' study-related labor by half, Studylog automates and streamlines the entire animal study process, making it Easier, faster and cheaper, so researchers have more time and resources to get their job done.

www.studylog.com

Become Our PREDiCT Series Partner

Drop me a line to find out more

Diane McKenna
Commercial Director, Tumor Models
T: +1 508 869 4452
E: Diane.McKenna@hansonwade.com

READY TO REGISTER?

3 EASY WAYS TO BOOK

www.tumor-models.com/register

Tel: +1 617 455 4188

Email: register@hansonwade.com

GET INVOLVED NOW TO SAVE UP TO $400!

Team Discounts

10% discount – 2 delegates

15 % discount - 3 delegates

20% discount – 4 or more delegates

PHARMA & BIOTECH	Register & Pay before Friday June 7, 2019	Standard Price
Conference + 3 Workshops	$3296 **(Save $400)**	$3496 **(Save $300)**
Conference + 2 Workshops	$2897 **(Save $400)**	$3097 **(Save $200)**
Conference + 1 Workshop	$2498 **(Save $300)**	$2698 **(Save $100)**
Conference Only	$2099 **(Save $200)**	$2299
Workshop Only	$499	

SOLUTIONS PROVIDER	Register & Pay before Friday June 7, 2019	Standard Price
Conference + 3 Workshops	$3996 **(Save $400)**	$4196 **(Save $300)**
Conference + 2 Workshops	$3597 **(Save $300)**	$3797 **(Save $200)**
Conference + 1 Workshop	$3198 **(Save $200)**	$3398 **(Save $100)**
Conference Only	$2799 **(Save $200)**	$2999
Workshop Only	$499	

ACADEMICS & STARTUPS	Register & Pay before Friday June 7, 2019	Standard Price
Conference + 3 Workshops	$2596 **(Save $400)**	$2696 **(Save $300)**
Conference + 2 Workshops	$2197 **(Save $300)**	$2297 **(Save $200)**
Conference + 1 Workshop	$1798 **(Save $200)**	$1898 **(Save $100)**
Conference Only	$1399 **(Save $100)**	$1499
Workshop Only	$499	

Academics & Small Biotech Rate subject to organizer approval. Please email info@hansonwade.com for more questions or to book.



VENUE

Revere Hotel Boston Common
200, Stuart St, Boston
MA 02116, USA

For further information or assistance, please visit: www.reverehotel.com